Around Rs 410 crore has been raised by Biotech startup Enzene Biosciences Ltd has secured $50 million in a fresh funding round led by its parent entity Alkem Laboratories Ltd, with participation from F-Prime Capital and Eight Roads Ventures.

Pune-based Enzene will deploy the new proceeds to boost its manufacturing capabilities and expand its footprints in India and abroad.

• Nepal Signs 7 MoUs with India for Projects 
• Trump to Hit Patented Drugs with a 100% Tariff 
• Government Looking to Talk with Airlines Amid Fuel Surcharge 
• Bank of Baroda Shares Slip Despite Q4 Global Advances Jumping 16.23%
• Pharma Stocks to be in Focus on Monday as Trump Tariff Reports Rattle Drug Sector

Enzene Biosciences Ltd subsidiary is Alkem Labs, a novel biologics focused on producing biosimilars, phytopharmaceuticals and synthetic peptides.

Meanwhile, Mumbai-headquartered Alkem produces branded generic drugs, generics, generic drugs, nutraceuticals, and active pharmaceutical ingredients, which it markets in global markets and India.

In 2022, the Biotech space saw a spate of investments as it started garnering investors’ traction post-pandemic. In July, biotechnology company String Bio Pvt Ltd made the first closure of its Series B round after raising $20 million led by Woodside Energy, with participation from Ankur Capital, Dare Ventures, Redstart and Zenfold Ventures.